Moxifloxacin: new fluoroquinolone for bacterial conjunctivitis


    loading  Checking for direct PDF access through Ovid

Abstract

KEY POINTSmoxifloxacin eye drops are a topical fluoroquinolone licensed for the treatment of bacterial conjunctivitis due to susceptible organismsmoxifloxacin's dual mode of action confers better activity against Gram-positive organisms compared to earlier fluoroquinolones while maintaining good activity against Gram-negative organismsthe dose is 1 drop in the affected eye(s) 3 times a day; the infection normally improves within 5 days and treatment should then continue for a further 2-3 days; 5ml=£9.80no dose adjustment necessary in children or in hepatic and renal impairment; not recommended for neonatesin clinical trials it was noninferior to levofloxacin eye drops and superior to placebo and trimethoprim/polymyxin Bcommon adverse effects include eye irritation and dysgeusiamoxifloxacin eye drops may be preferred to other quinolones in the management of bacterial conjunctivitis to minimise spread and achieve quicker clinical cureMoxifloxacin (Moxivig) is a fourth-generation fluoroquinolone for use in bacterial conjunctivitis. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Dr Adrian Tey discusses its potential role in the treatment of conjunctivitis.

    loading  Loading Related Articles